KUALA LUMPUR: Three more foreign players are expected to invest in Malaysian Bio-Xcell Sdn Bhd’s premier dedicated and managed biotechnology park in Nusajaya, Johor, Bio-Xcell.
Malaysian Bio-Xcell is a joint-venture company between Malaysian Biotechnology Corp (BiotechCorp) and UEM Land.
Chief executive officer Rizatuddin Ramli said one of the companies, which is involved in industrial biotechnology, would be confirmed next month, with the two other companies, which are involved in healthcare biotechnology, to be confirmed next year.
“For now, further details of these three companies are confidential,” he told a press conference at the soft launch of Bio-Xcell’s Central Hub.
He said the three potential tenants would join its current four clients India-based Biocon and Agila Biotech, United States-based Glycos Biotechnologies and French-based Metabolic Explorer.
The Central Hub features 28,149 sq m of gross floor area with more than 1858 sq m for science lab spaces as well as retail and F&B outlets, designed with green building elements.
Rizatuddin said the hub, a RM44.7mil development in the RM1bil Bio-Xcell park, is set to be completed in the third quarter of 2013 with tenancy expected in the beginning of the fourth quarter of next year.
At the ceremony, a collaboration proposal was also signed between BiotechCorp, Malaysian Bio-Xcell and Worldwide Holdings Bhd’s wholly-owned subsidiary, Worldwide Medivest Sdn Bhd.
Worldwide Medivest general manager Dr Abdul Reezal Abdul Latif said the agreement would give the three parties one year to discuss where Worldwide Medivest would be placed in the park.
“We currently have an ethylene gas sterilisation facility in Klang, and we aim to set up a similar plant in the park,” he added. — Bernama